Volatility in the economy is causing digital health companies to rethink their strategies for the remainder of 2025.

The ASX has opened higher despite renewed talk of tariffs in the US, which drove global markets lower in overnight trading.

Supply constraints have meant that the drug appears on the FDA's shortage list, which opens the door for compounding pharmacies to offer versions of the drug to patients. Last year, Novo Nordisk ...

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug ...

Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to ...

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But that’s reflective of the tough times the Danish maker of Ozempic and ...

Novo Nordisk has reduced its sales and profits forecasts ... Several telehealth companies such as Mochi Health and Hims & Hers began to offer compounded semaglutide during the shortage ...

LONDON/COPENHAGEN, May 7 (Reuters) - Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to reduce the time it takes to ...

COPENHAGEN/LONDON (Reuters) - Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for senior leadership positions in its U.S. business following ...

Novo Nordisk NOVO.B6.64%increase; green up pointing triangle lowered its full-year guidance as copycat versions of its blockbuster weight-loss and diabetes drugs in the U.S. hold back sales of its ...

Shares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.